



9-9-04

IFW

Express Mail No.: EV 452 773 240 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagat *et al.*

Confirmation No.: 1280

Application No.: 10/673,121

Group Art Unit: 3676

Filed: September 26, 2003

Examiner: To be assigned

For: INDAZOLE DERIVATIVES AS JNK
INHIBITORS AND COMPOSITIONS
AND METHODS RELATED
THERE TO

Attorney Docket No.: 10624-133-999
(CAM #700755-999132)

**TRANSMITTAL OF POWER OF ATTORNEY BY
ASSIGNEE AND EXCLUSION OF INVENTOR(S)
UNDER 37 C.F.R. § 3.71 WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith a Power of Attorney by Assignee and Exclusion of Inventor(s) under 37 C.F.R. § 3.71 with Statement Under 37 C.F.R. § 3.73(b), with copy of Limited Liability Company Articles of Organization-Conversion, executed by Dr. Alan J. Lewis, President, Signal Pharmaceuticals, LLC, the Assignee of the entire interest in the above-identified patent application by way of an Assignment from the inventors in the above-identified application to Signal Pharmaceuticals, LLC. Dr. Lewis is authorized to act on behalf of Signal Pharmaceuticals, LLC.

It is estimated that no fee is due in connection with this transmittal. In the event that a fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

Date September 8, 2004

By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)
For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130



Express Mail No. **EV 452 773 240 US**

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **Bhagwat *et al.***

Confirmation No.: **1280**

Serial No.: **10/673,121**

Art Unit: **3676**

Filed: **September 26, 2003**

Examiner: **To be assigned**

For: **INDAZOLE DERIVATIVES AS JNK INHIBITORS
AND COMPOSITIONS AND METHODS
RELATED THERETO**

Attorney Docket No.: **10624-133-999
(CAM #700755-999132)**

REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Signal Pharmaceuticals, LLC (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number 20583

as its attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: **Jones Day, 222 East 41st Street, New York, New York 10017**

Telephone: **(212) 326-3939**

Signal Pharmaceuticals, LLC is the:

- ☐ Applicant/Inventor
☒ Assignee of record of the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

Statement Under 37 C.F.R. 3.73(b)

Signal Pharmaceuticals, LLC states that it is:

- ☒ the assignee of the entire right, title, and interest; or
☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is %

in the patent application identified above by virtue of :

- ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

An assignment from: Shripad S. Bhagwat, Yoshitaka Satoh, Steven T. Sakata, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, and Rachel Ferri To: Signal Pharmaceuticals, Inc., which was recorded in the United States Patent and Trademark Office at Reel/Frame 012692/0030; and from Chris Buhr to Signal Pharmaceuticals, Inc., which was recorded in the United States Patent and Trademark Office at Reel/Frame 012680/0489; and

- ☒ the conversion of Signal Pharmaceuticals, Inc. to Signal Pharmaceuticals, LLC as evidenced by a certified copy of a Limited Liability Company Certificate of Amendment and a certified copy of a Limited Liability Company Articles of Organization - Conversion, each of which is attached hereto.
- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Signal Pharmaceuticals, LLC

Date:

8/20/04

Signature:



Typed Name:
Position/Title:

Alan J. Lewis, Ph.D.
President
Signal Pharmaceuticals, LLC

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

- ☒ Total of 1 form is submitted.



SECRETARY OF STATE

I, *Kevin Shelley*, Secretary of State of the State of California, hereby certify:

That the attached transcript of 1 page(s) has been compared with the record on file in this office, of which it purports to be a copy, and that it is full, true and correct.

IN WITNESS WHEREOF, I execute this certificate and affix the Great Seal of the State of California this day of

MAY - 6 2003



Kevin Shelley
Secretary of State



State of California
Kevin Shelley
Secretary of State

200312210170

File #

ENDORSED - FILED
in the office of the Secretary of State
of the State of California

APR 28 2003

KEVIN SHELLEY
Secretary of State

**LIMITED LIABILITY COMPANY
ARTICLES OF ORGANIZATION - CONVERSION**

IMPORTANT — READ ALL INSTRUCTIONS BEFORE COMPLETING THIS FORM

This Space For Filing Use Only

CONVERTED ENTITY INFORMATION

1. NAME OF LIMITED LIABILITY COMPANY

Signal Pharmaceuticals, LLC

2. THE PURPOSE OF THE LIMITED LIABILITY COMPANY IS TO ENGAGE IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH A LIMITED LIABILITY COMPANY MAY BE ORGANIZED UNDER THE BEVERLY-KILLEA LIMITED LIABILITY COMPANY ACT.

3. THE LIMITED LIABILITY COMPANY WILL BE MANAGED BY (CHECK ONLY ONE)

☐ ONE MANAGER ☐ MORE THAN ONE MANAGER ☒ SINGLE MEMBER LIMITED LIABILITY COMPANY ☐ ALL LIMITED LIABILITY COMPANY MEMBERS

4. TYPE OF BUSINESS OF THE LIMITED LIABILITY COMPANY (FOR INFORMATIONAL PURPOSES ONLY)

Biopharmaceutical

5. MAILING ADDRESS OF THE CHIEF EXECUTIVE OFFICE

4550 Towne Centre Court

CITY AND STATE

San Diego, CA

ZIP CODE

92121

6. CHECK THE APPROPRIATE PROVISION BELOW AND NAME THE AGENT FOR SERVICE OF PROCESS

☒ AN INDIVIDUAL RESIDING IN CALIFORNIA.☐ A CORPORATION WHICH HAS FILED A CERTIFICATE PURSUANT TO CALIFORNIA CORPORATIONS CODE SECTION 1505.

AGENT'S NAME Alan Lewis

7. ADDRESS OF AGENT FOR SERVICE OF PROCESS IN CA, IF AN INDIVIDUAL

5555 Oberlin Drive

CITY

San Diego

STATE

CA

ZIP CODE

92121

CONVERTING ENTITY INFORMATION

8. NAME OF CONVERTING ENTITY

Signal Pharmaceuticals, Inc.

9. FORM OF ENTITY

Corporation

10. JURISDICTION

California

11. CA SECRETARY OF STATE FILE NUMBER, IF ANY

C1825592

12. THE PRINCIPAL TERMS OF THE PLAN OF CONVERSION WERE APPROVED BY A VOTE OF THE NUMBER OF INTERESTS OR SHARES OF EACH CLASS THAT EQUATED OR EXCEEDED THE VOTE REQUIRED. IF A VOTE WAS REQUIRED, PROVIDE THE FOLLOWING:

NUMBER OF OUTSTANDING INTERESTS OF EACH CLASS ENTITLED TO VOTE

PERCENTAGE VOTE REQUIRED

1,000 shares of common stock

66.67

ADDITIONAL INFORMATION

13. NUMBER OF PAGES ATTACHED, IF ANY: _____ THE ATTACHED PAGES ARE INCORPORATED HEREIN BY THIS REFERENCE.

14. I DECLARE THAT I AM THE PERSON WHO EXECUTED THIS INSTRUMENT, WHICH EXECUTION IS MY ACT AND DEED.

SIGNATURE OF AUTHORIZED PERSON

SIGNATURE OF AUTHORIZED PERSON



John W. Jackson Chief Executive Officer

TYPE OR PRINT NAME AND TITLE OF AUTHORIZED PERSON

Robert J. Hugin Chief Financial Officer

TYPE OR PRINT NAME AND TITLE OF AUTHORIZED PERSON